Both antibodies and protein kinase vascular endothelial growth factor (VEGF) signaling pathway inhibitors, used in several solid cancers (e.g., colorectal and lung cancer), induce LVD and HF mainly due to cardiac hypertrophy and mitochondrial abnormalities [2]. Here, VEGFA is linked to cardiac hypertrophy.